Back to top
more

Solid Biosciences (SLDB)

(Delayed Data from NSDQ)

$9.58 USD

9.58
686,618

-0.19 (-1.94%)

Updated Aug 31, 2026 04:00 PM ET

After-Market: $9.56 -0.02 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (160 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Solid Biosciences' (SLDB) DMD Drug Gets Orphan Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) stock rises after the FDA grants the orphan drug designation to the company's novel gene-therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Zacks Equity Research

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

by Zacks Equity Research

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

Zacks Equity Research

Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday

by Zacks Equity Research

Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.

Zacks Equity Research

Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock Up

by Zacks Equity Research

Solid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy.

Zacks Equity Research

The Zacks Analyst Blog Highlights Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics

by Zacks Equity Research

Arcellx, Bristol Myers Squibb, Solid Biosciences, Vertex Pharmaceuticals and CRISPR Therapeutics are included in this Analyst Blog.

Zacks Equity Research

Biotech Stock Roundup: BMY's Drug Approval, VRTX & CRSP Gene Therapy Get MHRA Nod

by Zacks Equity Research

Bristol Myers (BMY) and Vertex (VRTX) drug approvals are in focus in the biotech sector.

Zacks Equity Research

Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND

by Zacks Equity Research

Solid Biosciences (SLDB) gains 28% as the FDA clears SGT-003, a gene therapy candidate, for clinical studies in the treatment of Duchenne Muscular Dystrophy.

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of 44.12% and 9.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of 15.85% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 51.61% and 29.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?